Abstract
The evidence from the literature does not support the notion that psychotropic drugs with central anticholinergic properties (antiparkinsonian drugs, neuroleptics, antidepressants) constitute a risk factor in tardive dyskinesia. Antiparkinsonian drugs tend to produce reversible increases in the severity of dyskinetic movements and can be used as pharmacological probes in the assessment of neuroleptic-induced movement disorders.
Publication types
-
Research Support, U.S. Gov't, P.H.S.
-
Review
MeSH terms
-
Acute Disease
-
Antidepressive Agents / adverse effects
-
Antiparkinson Agents / adverse effects
-
Antiparkinson Agents / pharmacology
-
Antiparkinson Agents / therapeutic use
-
Antipsychotic Agents / adverse effects
-
Antipsychotic Agents / pharmacology
-
Drug Interactions
-
Dyskinesia, Drug-Induced / drug therapy
-
Dyskinesia, Drug-Induced / etiology*
-
Humans
-
Parasympatholytics / adverse effects*
-
Risk
Substances
-
Antidepressive Agents
-
Antiparkinson Agents
-
Antipsychotic Agents
-
Parasympatholytics